telmisartan + chlorthalidone (Addpharma, Inc.)

AD-209-1C is a dual fixed-dose combination (FDC) of telmisartan (20 mg) and chlorthalidone (6.25 mg), developed by Addpharma Inc. (Gyeonggi-do, Republic of Korea). Telmisartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the angiotensin II type 1 (AT1) receptor, leading to vasodilation and reduced aldosterone secretion. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption by blocking the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule of the nephron. AD-209-1C was utilized as a comparator arm in a Phase 2 randomized, double-blind, parallel, multicenter clinical trial (NCT04541290) to evaluate the efficacy and safety of the triple combination therapy AD-209 (telmisartan/amlodipine/chlorthalidone) in patients with essential hypertension. It was specifically designed to isolate the contribution of the telmisartan and chlorthalidone components relative to the full triple combination and other dual combinations within the trial program.

Other names

telmisartan/chlorthalidone 20/6.25 mg